Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   30/04/2025
107,69 USD (+0,42%)
(+0,42%)   30/04/2025
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.
maandag 5 mei 2025, 22:00
Kwartaalcijfers (1ste kwartaal)

Neurocrine Biosciences, Inc. in het nieuws

30 april 2025 · Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia · Persbericht

24 april 2025 · Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry · Persbericht

14 april 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results · Persbericht

4 april 2025 · Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer · Persbericht

31 maart 2025 · Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia · Persbericht

20 maart 2025 · Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules · Persbericht

17 maart 2025 · Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules · Persbericht

11 maart 2025 · Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum · Persbericht

5 maart 2025 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults · Persbericht

12 september 2024 · Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Kevin Gorman

Werknemers: 1.252

Mijn selecties